PepGenPEPG
PEPG
About: PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Employees: 79
0
Funds holding %
of 7,334 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
18% more funds holding
Funds holding: 61 [Q4 2024] → 72 (+11) [Q1 2025]
0.76% more ownership
Funds ownership: 76.68% [Q4 2024] → 77.45% (+0.76%) [Q1 2025]
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
62% less capital invested
Capital invested by funds: $94.7M [Q4 2024] → $35.6M (-$59.2M) [Q1 2025]
70% less call options, than puts
Call options by funds: $35K | Put options by funds: $115K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$8
648%
upside
Avg. target
$8
648%
upside
High target
$8
648%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein | 648%upside $8 | Buy Maintained | 29 May 2025 |
Financial journalist opinion
Based on 88 articles about PEPG published over the past 30 days
Neutral
PRNewsWire
1 day ago
Faruqi & Faruqi Reminds PepGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - PEPG
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PepGen To Contact Him Directly To Discuss Their Options If you suffered purchased or acquired securities in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 9, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Neutral
GlobeNewsWire
2 days ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of PepGen Inc.(PEPG) Shareholders
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit.
Neutral
PRNewsWire
2 days ago
PepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG
NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025.
Neutral
GlobeNewsWire
3 days ago
PEPGEN (PEPG) FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options
Neutral
GlobeNewsWire
3 days ago
Lost Money on PepGen Inc. (PEPG)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).
Neutral
GlobeNewsWire
3 days ago
PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.
Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
GlobeNewsWire
3 days ago
PEPG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against PepGen Inc. (“PepGen” or “the Company”) (NASDAQ: PEPG) and certain of its officers.
Neutral
The Motley Fool
3 days ago
PepGen (PEPG) Q2 Loss Narrows 19.5%
PepGen (PEPG -3.88%), a biotechnology company focused on developing oligonucleotide-based therapies for neuromuscular diseases, released its earnings for the second quarter of 2025 on August 7, 2025. The biggest news was a GAAP net loss per share of $(0.70), which was better than the estimated $(0.85) GAAP loss expected by analysts.
Neutral
Business Wire
3 days ago
PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025. “This quarter, we made further progress in the development of our promising myotonic dystrophy type 1 program, PGN-EDODM1. With class-leading mean mis-.
Neutral
PRNewsWire
4 days ago
PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , Aug. 7, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PepGen Inc. ("PepGen" or "the Company") (NASDAQ: PEPG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 through March 3, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 8, 2025.
Charts implemented using Lightweight Charts™